February 18, 2016
Daiichi Sankyo said on February 17 that it has granted exclusive rights to US pharma giant Merck & Co. to market its anticoagulant Lixiana (edoxaban) in 13 European countries where it has no operational base. The 13 countries are Bulgaria,...read more